Compare BLDP & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | CMPX |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.0M | 926.7M |
| IPO Year | 1995 | N/A |
| Metric | BLDP | CMPX |
|---|---|---|
| Price | $2.58 | $6.18 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $2.24 | ★ $13.44 |
| AVG Volume (30 Days) | ★ 3.3M | 2.5M |
| Earning Date | 03-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,252,000.00 | N/A |
| Revenue This Year | $40.14 | N/A |
| Revenue Next Year | $11.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.33 |
| 52 Week High | $4.10 | $6.48 |
| Indicator | BLDP | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 60.13 |
| Support Level | $2.50 | $5.69 |
| Resistance Level | $2.82 | $6.40 |
| Average True Range (ATR) | 0.13 | 0.44 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 24.68 | 80.90 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.